Health care stocks were edging higher premarket Thursday, with the iShares Biotechnology ETF (IBB) and The Health Care Select Sector SPDR Fund (XLV) up 0.6%.
Neumora Therapeutics (NMRA) shares were down more than 82% after the company said that the phase 3 KOASTAL-1 study of navacaprant in treating major depressive disorder failed to meet its primary endpoint.
Hutchmed (China) (HCM) shares were up more than 5% after the company said overnight that the China National Medical Products Administration has accepted and granted priority review to its New Drug Application for the combination of Orpathys and Tagrisso for the treatment of patients with a specific type of non-small cell lung cancer.
ANI Pharmaceuticals (ANIP) shares were up over 4% after the company said it has launched its prucalopride tablets, the generic version of Motegrity, after receiving final approval from the US Food and Drug Administration.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。